Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
about
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetesPatient safety and minimizing risk with insulin administration - role of insulin degludecDistinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes MellitusA review of the pharmacological properties of insulin degludec and their clinical relevance.The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 DiabetesA Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
P2860
Q26784381-CA3C74C9-9FAC-46E3-9A9A-64FFB539089AQ27025548-833657E6-505A-4330-A90B-B052F656D815Q33785190-6E867B62-37E2-40FA-ACDB-ACE9D8F327DFQ34436383-B6D09BE4-365B-40D4-97DB-DDFD05A87BCDQ35894512-953712A1-5588-414F-9CE9-9E0D28C23518Q37575086-FE1E5749-4E72-4F50-8052-371BCB3502D0Q38241834-CC8D59F1-4003-4E28-A493-DA50EDFD1A8BQ38871135-2AE14CC2-B174-4492-BA3A-70EF0456E08CQ46358093-007CBB52-C2EC-4BB0-92B1-F8508B2B8FFF
P2860
Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@en
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@nl
type
label
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@en
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@nl
prefLabel
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@en
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@nl
P2093
P2860
P1433
P1476
Ultra-long pharmacokinetic pro ...... with type 1 diabetes mellitus.
@en
P2093
F Søndergaard
K Glettler
M Urschitz
P2860
P2888
P356
10.1007/S40266-013-0138-0
P577
2014-01-01T00:00:00Z